Azopt Related Published Studies
Well-designed clinical trials related to Azopt (Brinzolamide)
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. [2011.07]
[Comparative study of the pressure lowering efficacy and variations in the ocular pulse amplitude between fixed combinations of dorzolamide/timolol and brinzolamide/timolol]. [2011.05]
Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. [2010.08]
Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. [2009.09]
A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. [2009.06]
The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. [2009.04]
Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. [2009.03]
Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. [2008.10]
Medical control of intraocular pressure with brinzolamide 1% after phacoemulsification. [2008.10]
Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. [2008.04]
A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. [2008.04]
Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. [2007.07]
Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy. [2006.09]
A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. [2006.04]
The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. [2005.10]
The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma. [2005.04]
Comparing the effects of travoprost and brinzolamide on intraocular pressure after phacoemulsification. [2005.03]
Retinal peripapillary blood flow before and after topical brinzolamide. [2004.11]
Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. [2004.09]
Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. [2004.09]
Effect of topical brinzolamide 1% and brimonidine 0.2% on intraocular pressure after phacoemulsification. [2004.08]
Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. [2004.05]
Effects of brinzolamide on ocular haemodynamics in healthy volunteers. [2004.02]
Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. [2001.08]
Comparisons of intraocular-pressure- lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide. [2001.05]
Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects. [2000.02]
The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. [2000.02]
Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. [2000.01]
The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. [2000.01]
Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group. [2000.01]
Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. [1999.09]
Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. [1998.09]
Well-designed clinical trials possibly related to Azopt (Brinzolamide)
Effect of antiglaucoma agents on postoperative intraocular pressure after cataract surgery with Viscoat. [2007.11]
Influence of ocular hypotensive eyedrops on intraocular pressure fluctuation with postural change in eyes with normal-tension glaucoma. [2007.04]
Medical control of intraocular pressure after phacoemulsification. [2005.03]
Other research related to Azopt (Brinzolamide)
Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with
brinzolamide or brimonidine in patients with open-angle glaucoma or ocular
hypertension: results of a pooled analysis of two phase 3 studies. [2013]
Efficacy of single glaucoma drug in combined timolol XE, latanoprost and
brinzolamide therapy: a discontinuation study. [2012]
Effects of topical brinzolamide on infantile nystagmus syndrome waveforms: eyedrops for nystagmus. [2011.09]
The intraocular pressure reducing effect of brinzolamide as adjunctive therapy to latanoprost. [2011.08]
Effects of Topical Brinzolamide on Infantile Nystagmus Syndrome Waveforms: Eyedrops for Nystagmus. [2011.07.07]
[Adjunctive therapy with brinzolamide in patients on travoprost treatment]. [2011.05]
Signs and symptoms of ocular surface status in glaucoma patients switched from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month efficacy and tolerability, multicenter, open-label prospective study. [2011.04]
Intraocular Pressure-lowering Efficacy of Brinzolamide When Added to Travoprost/Timolol Fixed Combination as Adjunctive Therapy. [2010.11.02]
Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma. [2010.11]
Contrast sensitivity and optical quality of the eye after instillation of timolol maleate gel-forming solution and brinzolamide ophthalmic suspension. [2010.11]
[Mechanism of blurred vision after brinzolamide instillation] [2010.04]
[Mechanism of blurred vision after brinzolamide instillation]. [2010.04]
Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. [2009.10.02]
Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. [2009.08]
Comparing Diurnal and Nocturnal Effects of Brinzolamide and Timolol on Intraocular Pressure in Patients Receiving Latanoprost Monotherapy. [2009.01.19]
24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost. [2009]
Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension. [2009]
A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. [2008.12]
Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study. [2008.12]
Effects of topical administration of 1% brinzolamide on intraocular pressure in clinically normal horses. [2008.11]
A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. [2008.09]
Intraocular Pressure-Lowering Efficacy of Brinzolamide 1%/Timolol 0.5% Fixed Combination Compared with Brinzolamide 1% and Timolol 0.5% [2008.06.04]
Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: a randomized clinical trial. [2008.06]
Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma. [2008.06]
Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. [2008.05]
Short-term effect of topical brinzolamide on human central corneal thickness. [2008.05]
Brinzolamide. [2008.03]
Efficacy of brinzolamide and levobetaxolol in pediatric glaucomas: A randomized clinical trial. [2008.02.19]
Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database. [2008]
Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. [2007.06]
Comparison of the Ocular Hypotensive Efficacy of Adjunctive Brimonidine 0.15% or Brinzolamide 1% in Combination with Travoprost 0.004% [2007.05.15]
The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. [2006.11]
Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. [2006.09]
[Clinical investigation: the intraocular pressure-lowering efficacy and safety of brinzolamide combined with betaxolol] [2005.12]
Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. [2005.04]
Effects of topical administration of 1% brinzolamide on normal cat eyes. [2003.12]
Effects of brinzolamide on aqueous humor dynamics in monkeys and rabbits. [2003.10]
[Therapy of normal tension glaucoma: effect of brinzolamide on ocular haemodynamics] [2003.05]
Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension. [2003]
Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. [2003]
[The role of Brinzolamide 1% ophtalmic suspension in corneal edema] [2002]
Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. [2000.10]
Increased optic nerve head blood flow after 1 week of twice daily topical brinzolamide treatment in Dutch-belted rabbits. [2000.01]
Other possibly related research studies
[Cost-effectivity analysis of the most used antiglaucoma drugs] [2004.08]
Medical therapy cost considerations for glaucoma. [2003.07]
Cost analysis of glaucoma medications: a 3-year review. [2002.08]
Does glaucoma medication influence the diameter of the retinal arteriole in the human eye? (A pilot study using the retinal vessel analyser). [2001]
[Non surgical alternatives in the treatment of the primitive open angle glaucoma] [2001]
Advances in topical glaucoma therapy. [2002.03]
[Innovative glaucoma therapy. Glaucoma therapy with topical carbonic anhydrase inhibitors] [2001.10]
Update on topical carbonic anhydrase inhibitors. [2001.04]
Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. [2000.01]
Water-drinking test in patients with primary open-angle glaucoma while treated with different topical medications. [2005.06]
Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. [2005.07]
Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. [2004.01.05]
Acetazolamide: future perspective in topical glaucoma therapeutics. [2002.11.06]
New glaucoma medications in the geriatric population: efficacy and safety. [2002.05]
Antiglaucomatous drugs effects on optic nerve head flow: design, baseline and preliminary report. [2001]
Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating phthaloyl and phthalimido moieties. [2001]
Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties. [2001.07.09]
Perspectives in the medical treatment of glaucoma. [1999.04]
Topical therapies for glaucoma: what family physicians need to know. [1999.04.01]
[Therapeutic difficulties in neovascular glaucoma] [2006]
[Combined therapy in glaucoma treatment: travoprost 0.004% and brinzolamid] [2006]
Screening for drug-induced spoliation of the hydrogel optic of the AlphaCor artificial cornea. [2006.05]
[Blurred vision after instillation of topical carbonic anhydrase inhibitor] [2006.09]
|
